接受抗CD20治疗的新冠长期患者的核衣壳抗原血症
Nucleocapsid Antigenemia in Patients Receiving Anti-CD20 Therapy With Protracted COVID-19.
作者信息
Wilber Eli, Piantadosi Anne, Babiker Ahmed, McLendon Kaleb, O'Sick William, Fitts Eric, Webster Andrew S, Verkerke Hans, Kim James S, Phadke Varun K, Rouphael Nadine, Titanji Boghuma K, Blake William T, Howard-Anderson Jessica, Roback John D, Lam Wilbur A, Damhorst Gregory L
机构信息
Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
出版信息
Open Forum Infect Dis. 2022 Aug 17;9(8):ofac419. doi: 10.1093/ofid/ofac419. eCollection 2022 Aug.
Immunocompromised patients with prolonged coronavirus disease 2019 symptoms present diagnostic and therapeutic challenges. We measured viral nucleocapsid antigenemia in 3 patients treated with anti-CD20 immunotherapy who acquired severe acute respiratory syndrome coronavirus 2 infection and experienced protracted symptoms. Our results support nucleocapsid antigenemia as a marker of persistent infection and therapeutic response.
患有持续性2019冠状病毒病症状的免疫功能低下患者面临诊断和治疗挑战。我们对3例接受抗CD20免疫治疗并感染严重急性呼吸综合征冠状病毒2且症状迁延不愈的患者进行了病毒核衣壳抗原血症检测。我们的结果支持将核衣壳抗原血症作为持续性感染和治疗反应的标志物。
Zotero 插件